Floatz logo

Famitinib

Advanced Pancreatic Cancer

Jiangsu HengRui Medicine Co., Ltd.Small moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
81/ 100

Competitive context

31 Active assets in the Advanced Pancreatic Cancer cohort.

Asset / SponsorPhaseRating
S-1
Liu Xiufeng
Phase 4BB
Docetaxel
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3BB
Metformin
State University of New York - Downstate Medical Center
Phase 2BB
Fluzoparib
Jiangsu HengRui Medicine Co., Ltd.
Phase 3B
DYNAMOS
State University of New York - Downstate Medical Center
Phase 2B

View all 46 →

Same molecule, other indications

Famitinib is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
EGFR Activating MutationDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →